USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
AKTIV-DRY
Address:
2100 Central Ave., Suite 109
Boulder, CO 80301-
Phone:
N/A
URL:
N/A
EIN:
752993463
DUNS:
136952087
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $529,562.00 5
SBIR Phase II $2,059,541.00 3

Award List:

A New Process for Producing Phytosterol and Lycopene Nano- and Micro-Particles

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$79,985.00
Agency:
USDA
Principal Investigator:
Abstract:
Phytosterols and lycopene are neutraceuticals that are known antioxidants and cancer inhibitors. Unfortunately, they do not dissolve readily in body fluids and therefore present unique problems concerning their uptake by the blood stream. This project explores the ability to enhance the rate of… More

Inhalable IgG Synthesis For Influenza Immunoprophylaxis

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$99,600.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This Phase I SBIR proposal is the first step in the development of inhalable IgG microparticles for immunoprophylaxis against Influenza A, a category C Priority Pathogen. In Phase I, Aktiv-Dry will simultaneously stabilize, dry, and micronize IgG antibody… More

Product Formulation and Process Design for Commercial Production of Soluable Phytosterols

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$296,000.00
Agency:
USDA
Principal Investigator:
Abstract:
Commercially available products rich in phytosterol may now be used to cut serum low-density lipoprotein by as much as 14 percent. Unfortunately, phytosterols are poorly soluble and therefore present unique problems concerning their ability to suppress cholesterol absorption in the gut. This… More

Development of a Micronized Needle-Free Nicotine Vaccine for Smoking Cessation an

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$99,989.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Aktiv-Dry LLC, in collaboration with Nabi Biopharmaceuticals, proposes to develop and evaluate in animal models the needle-free respiratory delivery of fine dry powder nicotine vaccine. While syringe and needle have been a common vaccine administration mechanism,… More

Aktiv-Neb: A Dry Powder Inhaler for Anti-RSV siRNA Microparticles

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$99,990.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This Small Business Innovation Research Phase I project aims to develop a novel dry powder inhalation system, Aktiv-NebTM, for delivering antiviral drug (siRNAs) powders, to the respiratory systems of infants and young children as an intervention strategy for… More

Development of a Micronized Needle-Free Nicotine Vaccine for Smoking Cessation an

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$823,623.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Aktiv-Dry LLC, in collaboration with Nabi Biopharmaceuticals, proposes to develop and evaluate in animal models the needle-free respiratory delivery of fine dry powder nicotine vaccine. While syringe and needle have bee n a common vaccine administration… More

A new, rapidly dissolving and thermally stable dry powder Hepatitis-B vaccine

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$939,918.00
Agency:
HHS
Principal Investigator:
Stephen P. Cape – 303-350-3060
Abstract:
DESCRIPTION (provided by applicant): The overarching goal of this project is to move a new, dry powder formulation of Hepatitis-B vaccine on its path to commercialization. In the Phase I SBIR we tested in vitro three Hep-B dry powder formulations of commercially available Shanvac-B and demonstrated… More

Thermostable Sublingual Measles Vaccine Dry Wafers

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$149,998.00
Agency:
HHS
Principal Investigator:
Stephen Cape – (303) 350-3060
Abstract:
"Measles is a highly contagious, human disease that is spread by the respiratory route, and, in the developing world, remains a leading cause of death due to vaccine-preventable infectious diseases in children younger than 5 years. The most recent estimates are that there were 139,300 deaths… More